25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Alseres Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Alseres together

I guess you are interested in Alseres Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Alseres Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Alseres Pharmaceuticals Inc

I send you an email if I find something interesting about Alseres Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Alseres (30 sec.)










1.2. What can you expect buying and holding a share of Alseres? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
20.0%

What is your share worth?

Current worth
$-1,739.81
Expected worth in 1 year
$8,745.62
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
$10,485.43
Return On Investment
104,854,271.3%

For what price can you sell your share?

Current Price per Share
$0.01
Expected price per share
$0.01 - $0.01
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Alseres (5 min.)




Live pricePrice per Share (EOD)
$0.01
Intrinsic Value Per Share
$-8,682.52 - $17,291.54
Total Value Per Share
$-10,422.33 - $15,551.73

2.2. Growth of Alseres (5 min.)




Is Alseres growing?

Current yearPrevious yearGrowGrow %
How rich?-$10.6m-$26.7m$16m150.7%

How much money is Alseres making?

Current yearPrevious yearGrowGrow %
Making money-$941.5k-$1.6m$703.9k74.8%
Net Profit Margin-198.7%-310.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Alseres (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Alseres?

Welcome investor! Alseres's management wants to use your money to grow the business. In return you get a share of Alseres.

First you should know what it really means to hold a share of Alseres. And how you can make/lose money.

Speculation

The Price per Share of Alseres is $0.01. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alseres.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alseres, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1,739.81. Based on the TTM, the Book Value Change Per Share is $2,621.36 per quarter. Based on the YOY, the Book Value Change Per Share is $633.48 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alseres.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-153.67-1,536,688.4%-153.67-1,536,688.4%-268.56-2,685,614.5%-525.78-5,257,817.6%-1,723.69-17,236,933.8%
Usd Book Value Change Per Share2,621.3626,213,567.8%2,621.3626,213,567.8%633.486,334,832.7%958.179,581,701.6%-371.72-3,717,224.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%8.4384,341.4%
Usd Total Gains Per Share2,621.3626,213,567.8%2,621.3626,213,567.8%633.486,334,832.7%958.179,581,701.6%-363.29-3,632,883.3%
Usd Price Per Share0.02-0.02-0.08-0.13-1.05-
Price to Earnings Ratio0.00-0.00-0.00-0.00-0.00-
Price-to-Total Gains Ratio0.00-0.00-0.00-0.00-0.00-
Price to Book Ratio0.00-0.00-0.00-0.00-0.00-
Price-to-Total Gains Ratio0.00-0.00-0.00-0.00-0.00-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.01
Number of shares100000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share2,621.36958.17
Usd Total Gains Per Share2,621.36958.17
Gains per Quarter (100000 shares)262,135,678.1595,817,016.48
Gains per Year (100000 shares)1,048,542,712.58383,268,065.94
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10104854271310485427030383268066383268056
20209708542520970854160766536132766536122
3031456281383145628129011498041981149804188
4041941708504194170842015330722641533072254
5052427135635242713555019163403301916340320
6062912562766291256268022996083962299608386
7073397989887339798981026828764622682876452
8083883417018388341694030661445283066144518
9094368844139436884407034494125933449412584
1001048542712610485427120038326806593832680650

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%1.09.00.010.0%1.022.00.04.3%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%5.05.00.050.0%9.014.00.039.1%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%2.00.08.020.0%2.00.021.08.7%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%5.05.00.050.0%9.014.00.039.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Alseres Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2621.3572621.3570%633.483+314%958.170+174%-371.722+114%
Book Value Per Share---1739.810-1739.8100%-4361.167+151%-5267.056+203%-3784.817+118%
Current Ratio--0.1970.1970%0.089+120%0.075+162%0.700-72%
Debt To Asset Ratio--28.65428.6540%28.6700%80.462-64%46.466-38%
Debt To Equity Ratio----0%-0%-0%0.381-100%
Dividend Per Share----0%-0%-0%8.434-100%
Eps---153.669-153.6690%-268.561+75%-525.782+242%-1723.693+1022%
Free Cash Flow Per Share---275.327-275.3270%-155.451-44%-523.870+90%-1500.704+445%
Free Cash Flow To Equity Per Share---128.436-128.4360%-19.474-85%-40.870-68%-280.340+118%
Gross Profit Margin--1.0271.0270%1.000+3%1.005+2%1.003+2%
Intrinsic Value_10Y_max--17291.536--------
Intrinsic Value_10Y_min---8682.524--------
Intrinsic Value_1Y_max--155.136--------
Intrinsic Value_1Y_min---1355.453--------
Intrinsic Value_3Y_max--1668.433--------
Intrinsic Value_3Y_min---3676.294--------
Intrinsic Value_5Y_max--4631.256--------
Intrinsic Value_5Y_min---5545.031--------
Market Cap61.270-135%143.985143.9850%490.160-71%817.613-82%6437.774-98%
Net Profit Margin---1.987-1.9870%-3.100+56%-1.018-49%-0.509-74%
Operating Margin---1.028-1.0280%-2.282+122%-0.662-36%-0.331-68%
Operating Ratio--3.0473.0470%3.284-7%1.266+141%0.633+381%
Pb Ratio0.000+57%0.0000.0000%0.000+36%0.000+80%0.001-102%
Pe Ratio0.000+57%0.0000.0000%0.000+95%0.001-118%0.000-299%
Price Per Share0.010-135%0.0240.0240%0.080-71%0.133-82%1.050-98%
Price To Free Cash Flow Ratio0.000+57%0.0000.0000%-0.001+503%0.000+275%-0.001+553%
Price To Total Gains Ratio0.000-135%0.0000.0000%0.000-93%0.000-91%0.000+2648%
Quick Ratio--0.3200.3200%0.177+81%0.118+172%1.143-72%
Return On Assets---2.443-2.4430%-1.704-30%-6.709+175%-7.832+221%
Return On Equity----0%-0%-0%-2.1230%
Total Gains Per Share--2621.3572621.3570%633.483+314%958.170+174%-363.288+114%
Usd Book Value---10659818.000-10659818.0000%-26720871.000+151%-32555703.000+205%-23331800.800+119%
Usd Book Value Change Per Share--2621.3572621.3570%633.483+314%958.170+174%-371.722+114%
Usd Book Value Per Share---1739.810-1739.8100%-4361.167+151%-5267.056+203%-3784.817+118%
Usd Dividend Per Share----0%-0%-0%8.434-100%
Usd Eps---153.669-153.6690%-268.561+75%-525.782+242%-1723.693+1022%
Usd Free Cash Flow---1686929.000-1686929.0000%-952449.000-44%-3227503.800+91%-9203689.500+446%
Usd Free Cash Flow Per Share---275.327-275.3270%-155.451-44%-523.870+90%-1500.704+445%
Usd Free Cash Flow To Equity Per Share---128.436-128.4360%-19.474-85%-40.870-68%-280.340+118%
Usd Market Cap61.270-135%143.985143.9850%490.160-71%817.613-82%6437.774-98%
Usd Price Per Share0.010-135%0.0240.0240%0.080-71%0.133-82%1.050-98%
Usd Profit---941529.000-941529.0000%-1645476.000+75%-3146747.400+234%-10523710.600+1018%
Usd Revenue--473730.000473730.0000%530720.000-11%200890.000+136%100445.000+372%
Usd Total Gains Per Share--2621.3572621.3570%633.483+314%958.170+174%-363.288+114%
 EOD+1 -7MRQTTM+0 -0YOY+18 -145Y+21 -1110Y+24 -11

3.3 Fundamental Score

Let's check the fundamental score of Alseres Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.000
Price to Book Ratio (EOD)Between0-10.000
Net Profit Margin (MRQ)Greater than0-1.987
Operating Margin (MRQ)Greater than0-1.028
Quick Ratio (MRQ)Greater than10.320
Current Ratio (MRQ)Greater than10.197
Debt to Asset Ratio (MRQ)Less than128.654
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-2.443
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Alseres Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than500.000
Ma 20Greater thanMa 500.010
Ma 50Greater thanMa 1000.010
Ma 100Greater thanMa 2000.010
OpenGreater thanClose0.010
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Alseres Pharmaceuticals Inc

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

Fundamental data was last updated by Penke on 2024-11-17 22:51:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Alseres earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Alseres to the Biotechnology industry mean.
  • A Net Profit Margin of -198.7% means that $-1.99 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alseres Pharmaceuticals Inc:

  • The MRQ is -198.7%. The company is making a huge loss. -2
  • The TTM is -198.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-198.7%TTM-198.7%0.0%
TTM-198.7%YOY-310.0%+111.3%
TTM-198.7%5Y-101.8%-97.0%
5Y-101.8%10Y-50.9%-50.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-198.7%-115.9%-82.8%
TTM-198.7%-210.8%+12.1%
YOY-310.0%-214.5%-95.5%
5Y-101.8%-342.2%+240.4%
10Y-50.9%-464.5%+413.6%
4.3.1.2. Return on Assets

Shows how efficient Alseres is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Alseres to the Biotechnology industry mean.
  • -244.3% Return on Assets means that Alseres generated $-2.44 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alseres Pharmaceuticals Inc:

  • The MRQ is -244.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -244.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-244.3%TTM-244.3%0.0%
TTM-244.3%YOY-170.4%-73.9%
TTM-244.3%5Y-670.9%+426.6%
5Y-670.9%10Y-783.2%+112.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-244.3%-11.1%-233.2%
TTM-244.3%-11.7%-232.6%
YOY-170.4%-11.3%-159.1%
5Y-670.9%-12.7%-658.2%
10Y-783.2%-14.3%-768.9%
4.3.1.3. Return on Equity

Shows how efficient Alseres is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Alseres to the Biotechnology industry mean.
  • 0.0% Return on Equity means Alseres generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alseres Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-212.3%+212.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.2%+14.2%
TTM--15.8%+15.8%
YOY--13.9%+13.9%
5Y--18.5%+18.5%
10Y-212.3%-19.5%-192.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Alseres Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Alseres is operating .

  • Measures how much profit Alseres makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Alseres to the Biotechnology industry mean.
  • An Operating Margin of -102.8% means the company generated $-1.03  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alseres Pharmaceuticals Inc:

  • The MRQ is -102.8%. The company is operating very inefficient. -2
  • The TTM is -102.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-102.8%TTM-102.8%0.0%
TTM-102.8%YOY-228.2%+125.4%
TTM-102.8%5Y-66.2%-36.6%
5Y-66.2%10Y-33.1%-33.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-102.8%-258.6%+155.8%
TTM-102.8%-318.3%+215.5%
YOY-228.2%-224.0%-4.2%
5Y-66.2%-386.5%+320.3%
10Y-33.1%-497.6%+464.5%
4.3.2.2. Operating Ratio

Measures how efficient Alseres is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.05 means that the operating costs are $3.05 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Alseres Pharmaceuticals Inc:

  • The MRQ is 3.047. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.047. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.047TTM3.0470.000
TTM3.047YOY3.284-0.237
TTM3.0475Y1.266+1.781
5Y1.26610Y0.633+0.633
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0472.594+0.453
TTM3.0473.360-0.313
YOY3.2843.299-0.015
5Y1.2664.788-3.522
10Y0.6336.528-5.895
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Alseres Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Alseres is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.20 means the company has $0.20 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Alseres Pharmaceuticals Inc:

  • The MRQ is 0.197. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.197. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.197TTM0.1970.000
TTM0.197YOY0.089+0.108
TTM0.1975Y0.075+0.122
5Y0.07510Y0.700-0.625
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1973.658-3.461
TTM0.1973.874-3.677
YOY0.0894.672-4.583
5Y0.0755.960-5.885
10Y0.7006.277-5.577
4.4.3.2. Quick Ratio

Measures if Alseres is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Alseres to the Biotechnology industry mean.
  • A Quick Ratio of 0.32 means the company can pay off $0.32 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alseres Pharmaceuticals Inc:

  • The MRQ is 0.320. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.320. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.320TTM0.3200.000
TTM0.320YOY0.177+0.144
TTM0.3205Y0.118+0.202
5Y0.11810Y1.143-1.025
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3203.104-2.784
TTM0.3203.426-3.106
YOY0.1774.498-4.321
5Y0.1185.933-5.815
10Y1.1436.426-5.283
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Alseres Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Alseres assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Alseres to Biotechnology industry mean.
  • A Debt to Asset Ratio of 28.65 means that Alseres assets are financed with 2,865.4% credit (debt) and the remaining percentage (100% - 2,865.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Alseres Pharmaceuticals Inc:

  • The MRQ is 28.654. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 28.654. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ28.654TTM28.6540.000
TTM28.654YOY28.670-0.016
TTM28.6545Y80.462-51.808
5Y80.46210Y46.466+33.996
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ28.6540.354+28.300
TTM28.6540.345+28.309
YOY28.6700.311+28.359
5Y80.4620.366+80.096
10Y46.4660.382+46.084
4.5.4.2. Debt to Equity Ratio

Measures if Alseres is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Alseres to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alseres Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y0.381-0.381
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.398-0.398
TTM-0.437-0.437
YOY-0.378-0.378
5Y-0.452-0.452
10Y0.3810.495-0.114
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Alseres generates.

  • Above 15 is considered overpriced but always compare Alseres to the Biotechnology industry mean.
  • A PE ratio of 0.00 means the investor is paying $0.00 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alseres Pharmaceuticals Inc:

  • The EOD is 0.000. Based on the earnings, the company is expensive. -2
  • The MRQ is 0.000. Based on the earnings, the company is expensive. -2
  • The TTM is 0.000. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ0.000+0.000
MRQ0.000TTM0.0000.000
TTM0.000YOY0.000+0.000
TTM0.0005Y0.001-0.001
5Y0.00110Y0.000+0.001
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-2.160+2.160
MRQ0.000-2.428+2.428
TTM0.000-3.145+3.145
YOY0.000-3.304+3.304
5Y0.001-6.080+6.081
10Y0.000-6.625+6.625
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alseres Pharmaceuticals Inc:

  • The EOD is 0.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 0.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 0.000. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ0.000+0.000
MRQ0.000TTM0.0000.000
TTM0.000YOY-0.001+0.000
TTM0.0005Y0.000+0.000
5Y0.00010Y-0.001+0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-2.980+2.980
MRQ0.000-3.295+3.295
TTM0.000-3.682+3.682
YOY-0.001-4.523+4.522
5Y0.000-8.162+8.162
10Y-0.001-9.239+9.238
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Alseres is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.00 means the investor is paying $0.00 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Alseres Pharmaceuticals Inc:

  • The EOD is 0.000. Based on the equity, the company is expensive. -2
  • The MRQ is 0.000. Based on the equity, the company is expensive. -2
  • The TTM is 0.000. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ0.000+0.000
MRQ0.000TTM0.0000.000
TTM0.000YOY0.000+0.000
TTM0.0005Y0.000+0.000
5Y0.00010Y0.001-0.001
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.0001.869-1.869
MRQ0.0002.027-2.027
TTM0.0002.365-2.365
YOY0.0002.419-2.419
5Y0.0003.668-3.668
10Y0.0014.362-4.361
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2013-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets385
Total Liabilities11,045
Total Stockholder Equity-10,660
 As reported
Total Liabilities 11,045
Total Stockholder Equity+ -10,660
Total Assets = 385

Assets

Total Assets385
Total Current Assets325
Long-term Assets61
Total Current Assets
Cash And Cash Equivalents 114
Short-term Investments 207
Total Current Assets  (as reported)325
Total Current Assets  (calculated)321
+/- 4
Long-term Assets
Other Assets 61
Long-term Assets  (as reported)61
Long-term Assets  (calculated)61
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,648
Long-term Liabilities9,397
Total Stockholder Equity-10,660
Total Current Liabilities
Short-term Debt 506
Short Long Term Debt 8,320
Accounts payable 500
Other Current Liabilities 1,075
Total Current Liabilities  (as reported)1,648
Total Current Liabilities  (calculated)10,400
+/- 8,752
Long-term Liabilities
Long term Debt 7,820
Other Liabilities 1,187
Deferred Long Term Liability 61
Long-term Liabilities  (as reported)9,397
Long-term Liabilities  (calculated)9,067
+/- 330
Total Stockholder Equity
Common Stock306
Retained Earnings -199,635
Accumulated Other Comprehensive Income 7
Other Stockholders Equity 188,662
Total Stockholder Equity (as reported)-10,660
Total Stockholder Equity (calculated)-10,660
+/-0
Other
Cash and Short Term Investments 321
Common Stock Shares Outstanding 6
Current Deferred Revenue74
Liabilities and Stockholders Equity 385
Net Debt 7,706
Net Tangible Assets -10,660
Net Working Capital -1,324
Preferred Stock Total Equity 390
Short Long Term Debt Total 7,820



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311999-12-311998-12-311997-12-311996-12-311995-12-311994-12-311993-12-311992-12-311991-12-311990-12-311989-12-311988-12-311987-12-311986-12-311985-12-31
> Total Assets 
2,100
4,200
11,700
3,600
6,800
12,800
21,400
18,800
13,400
3,700
6,600
26,200
18,600
12,300
16,100
20,712
11,426
8,528
17,433
2,545
10,515
2,369
5,624
845
791
461
171
966
385
3859661714617918455,6242,36910,5152,54517,4338,52811,42620,71216,10012,30018,60026,2006,6003,70013,40018,80021,40012,8006,8003,60011,7004,2002,100
   > Total Current Assets 
2,000
4,100
11,200
3,000
5,800
11,000
18,700
14,800
12,200
3,400
2,800
22,400
14,700
8,500
15,600
20,473
10,899
7,394
11,927
1,788
9,816
1,851
5,192
317
388
209
168
900
325
3259001682093883175,1921,8519,8161,78811,9277,39410,89920,47315,6008,50014,70022,4002,8003,40012,20014,80018,70011,0005,8003,00011,2004,1002,000
       Cash And Cash Equivalents 
1,300
2,700
9,000
2,400
5,000
9,800
3,700
2,800
4,300
2,700
2,100
8,600
1,700
100
300
407
287
794
6,088
153
579
1,509
2,933
74
315
99
136
17
114
1141713699315742,9331,5095791536,0887942874073001001,7008,6002,1002,7004,3002,8003,7009,8005,0002,4009,0002,7001,300
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,700
19,362
10,012
6,178
4,876
1,490
8,751
0
1,241
80
39
96
27
881
207
207881279639801,24108,7511,4904,8766,17810,01219,36214,70000000000000000
       Net Receivables 
600
1,300
1,600
0
400
400
300
11,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000011,50030040040001,6001,300600
       Other Current Assets 
100
100
600
600
0
400
14,700
500
7,900
700
700
13,800
13,000
8,400
600
704
600
422
516
145
487
343
1,018
243
73
14
5
3
14
143514732431,0183434871455164226007046008,40013,00013,8007007007,90050014,7004000600600100100
   > Long-term Assets 
100
100
500
600
1,000
1,800
2,700
4,000
1,200
300
3,800
3,800
3,900
3,800
500
239
527
1,134
5,506
756
700
518
431
528
403
252
2
66
61
616622524035284315187007565,5061,1345272395003,8003,9003,8003,8003001,2004,0002,7001,8001,000600500100100
       Property Plant Equipment 
0
100
300
500
800
1,600
2,100
3,500
900
-200
100
100
100
-200
-200
42
524
785
605
400
276
136
88
179
106
48
2
1
0
012481061798813627640060578552442-200-200100100100-2009003,5002,1001,6008005003001000
       Intangible Assets 
100
100
100
100
100
200
200
300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000300200200100100100100100
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
197
4
349
4,901
357
423
382
343
349
297
204
0
65
61
616502042973493433824233574,9013494197000000000000000
> Total Liabilities 
1,000
800
1,400
1,200
1,400
2,800
3,200
3,300
2,700
1,300
5,400
2,100
2,000
1,800
6,400
1,661
1,804
5,705
5,317
1,976
2,624
18,941
28,038
40,859
48,300
47,747
30,773
27,687
11,045
11,04527,68730,77347,74748,30040,85928,03818,9412,6241,9765,3175,7051,8041,6616,4001,8002,0002,1005,4001,3002,7003,3003,2002,8001,4001,2001,4008001,000
   > Total Current Liabilities 
1,100
800
1,300
1,200
1,000
2,400
2,000
2,900
2,500
1,200
3,100
2,100
2,000
1,700
1,800
1,661
1,804
1,835
1,506
1,976
2,350
18,705
3,770
4,941
4,924
42,288
30,425
10,067
1,648
1,64810,06730,42542,2884,9244,9413,77018,7052,3501,9761,5061,8351,8041,6611,8001,7002,0002,1003,1001,2002,5002,9002,0002,4001,0001,2001,3008001,100
       Short-term Debt 
0
0
0
0
100
100
200
200
200
100
1,500
100
0
0
0
0
0
0
0
0
0
8,000
0
45
1,401
33,726
27,728
6,410
506
5066,41027,72833,7261,4014508,0000000000001001,5001002002002001001000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29,000
21,828
6,735
8,320
8,3206,73521,82829,0000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
1,800
1,700
900
100
1,000
1,900
2,000
1,700
1,800
1,661
1,804
1,835
1,506
1,976
2,289
10,674
2,269
4,896
3,460
3,577
1,416
2,197
500
5002,1971,4163,5773,4604,8962,26910,6742,2891,9761,5061,8351,8041,6611,8001,7002,0001,9001,0001009001,7001,800000000
       Other Current Liabilities 
0
0
0
0
900
2,300
0
1,000
1,400
1,000
600
100
0
0
0
0
0
0
34
256
61
31
1,501
4,896
63
4,985
2,697
1,386
1,075
1,0751,3862,6974,985634,8961,5013161256340000001006001,0001,4001,00002,3009000000
   > Long-term Liabilities 
-100
0
100
100
400
400
1,200
400
200
100
2,300
0
0
100
4,600
0
0
3,870
3,811
0
274
236
24,268
35,917
43,376
5,459
348
17,620
9,397
9,39717,6203485,45943,37635,91724,26823627403,8113,870004,600100002,3001002004001,2004004001001000-100
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
274
236
933
2,461
4,153
31
0
17,250
1,187
1,18717,2500314,1532,46193323627400000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
65
61
6165000000000000000000000000000
> Total Stockholder Equity
1,100
3,400
10,300
2,400
5,400
10,000
18,200
15,500
10,700
2,400
1,200
24,100
16,600
10,500
9,700
19,051
9,623
2,823
12,116
569
7,891
-16,572
-22,414
-40,013
-47,509
-47,286
-30,602
-26,721
-10,660
-10,660-26,721-30,602-47,286-47,509-40,013-22,414-16,5727,89156912,1162,8239,62319,0519,70010,50016,60024,1001,2002,40010,70015,50018,20010,0005,4002,40010,3003,4001,100
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
200
207
208
224
325
69
165
166
208
214
256
268
306
306
306
3063063062682562142081661656932522420820720000000000000000
   Retained Earnings 
-8,500
-13,900
-24,200
-37,300
-46,000
-54,600
-68,400
-84,400
-109,500
-117,800
-19,300
-25,300
-33,300
-40,200
54,100
-64,782
-75,035
-86,028
-94,396
-105,647
-117,148
-143,504
-163,052
-183,899
-194,678
-194,166
-197,048
-198,694
-199,635
-199,635-198,694-197,048-194,166-194,678-183,899-163,052-143,504-117,148-105,647-94,396-86,028-75,035-64,78254,100-40,200-33,300-25,300-19,300-117,800-109,500-84,400-68,400-54,600-46,000-37,300-24,200-13,900-8,500
   Capital Surplus 00000000000000000000000000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
9,600
17,300
34,500
39,700
51,400
64,600
86,600
99,900
120,200
120,200
20,500
49,400
49,900
50,700
-44,700
83,605
84,319
88,512
202,390
205,300
124,887
126,766
140,420
143,672
146,913
146,612
166,519
172,345
188,662
188,662172,345166,519146,612146,913143,672140,420126,766124,887205,300202,39088,51284,31983,605-44,70050,70049,90049,40020,500120,200120,20099,90086,60064,60051,40039,70034,50017,3009,600



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2013-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue474
Cost of Revenue-24
Gross Profit450450
 
Operating Income (+$)
Gross Profit450
Operating Expense-1,420
Operating Income-565-970
 
Operating Expense (+$)
Research Development0
Selling General Administrative1,394
Selling And Marketing Expenses26
Operating Expense1,4201,420
 
Net Interest Income (+$)
Interest Income0
Interest Expense-455
Other Finance Cost-455
Net Interest Income0
 
Pretax Income (+$)
Operating Income-565
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-942-593
EBIT - interestExpense = -942
-487
-487
Interest Expense455
Earnings Before Interest and Taxes (EBIT)-487-487
Earnings Before Interest and Taxes (EBITDA)-486
 
After tax Income (+$)
Income Before Tax-942
Tax Provision-0
Net Income From Continuing Ops-942-942
Net Income-942
Net Income Applicable To Common Shares-942
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses1,420
Total Other Income/Expenses Net280
 

Technical Analysis of Alseres
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alseres. The general trend of Alseres is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alseres's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alseres Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.01 < 0.01 < 0.01.

The bearish price targets are: 0.01 > 0.01 > 0.01.

Tweet this
Alseres Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alseres Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alseres Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alseres Pharmaceuticals Inc. The current macd is 0.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Alseres price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Alseres. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Alseres price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Alseres Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartAlseres Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Alseres Pharmaceuticals Inc. The current adx is 0.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is 0/(-7 +7).

  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Alseres Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Alseres Pharmaceuticals Inc. The current sar is 0.01.

Alseres Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Alseres Pharmaceuticals Inc. The current rsi is 0. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 1/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
Alseres Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartAlseres Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Alseres Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Alseres price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Alseres Pharmaceuticals Inc Daily Stochastic Oscillator ChartAlseres Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Alseres Pharmaceuticals Inc. The current cci is -66.66666667.

Alseres Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartAlseres Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Alseres Pharmaceuticals Inc. The current cmo is 0.

Alseres Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartAlseres Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Alseres Pharmaceuticals Inc. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Alseres Pharmaceuticals Inc Daily Williams %R ChartAlseres Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Alseres Pharmaceuticals Inc.

Alseres Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Alseres Pharmaceuticals Inc. The current atr is 0.

Alseres Pharmaceuticals Inc Daily Average True Range (ATR) ChartAlseres Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Alseres Pharmaceuticals Inc. The current obv is 0.

Alseres Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartAlseres Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Alseres Pharmaceuticals Inc. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Alseres Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartAlseres Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Alseres Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal

6.3. Candlestick Patterns

Alseres Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Alseres Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than500.000
Ma 20Greater thanMa 500.010
Ma 50Greater thanMa 1000.010
Ma 100Greater thanMa 2000.010
OpenGreater thanClose0.010
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Alseres with someone you think should read this too:
  • Are you bullish or bearish on Alseres? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Alseres? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Alseres Pharmaceuticals Inc

I send you an email if I find something interesting about Alseres Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Alseres Pharmaceuticals Inc.

Receive notifications about Alseres Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.